INDIANAPOLIS (Inside Indiana Business) – Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has signed a research collaboration and licensing agreement with Biolojic Design, an Israel-based biopharmaceutical company, to discover and discover an antibody-based therapy for diabetes develop .
Under the agreement, Lilly will use Biolojic’s AI-based platform to discover a multispecific antibody for the development of therapies.
Did you miss last weekend’s #IIBTV with Gerry Dick? Get going with the Inside INdiana Business Television Podcast! Download or stream it for FREE from your favorite podcast provider. More information here: http://bit.ly/IIBPodcasts
“Lilly continues to seek novel ways to develop new drugs, and Biolojic’s multi-specific antibody platform is a promising approach,” said Ruth Gimeno, Lilly vice president of diabetes and metabolic research. “We look forward to working closely with the Biolojic scientific team and leveraging their expertise to discover and develop a potential antibody-based therapy for people with diabetes.”
According to Lilly, Biolojic Design could receive potential development and commercialization milestones of up to $ 121 million.
Biolojic could also receive tiered royalties on product sales based on whether or not Lilly brings a therapy to market as a result of the collaboration.
“Although our internal pipeline focuses on computational antibodies for use in oncology and autoimmune diseases, we are excited to partner with Lilly and leverage our platform to develop potential therapies for diabetes,” said Yanay Ofran, CEO of Biolojic.